Das Schweizer MR-in-RT-Symposium 2026 bringt internationale Experten zusammen, um aktuelle Entwicklungen und Zukunftsperspektiven in der MR-gesteuerten Strahlentherapie zu erörtern. Von adaptiven Behandlungskonzepten und der Integration in Arbeitsabläufe bis hin zu KI-gestützten Innovationen und translationaler Forschung bietet das Symposium prägnante Einblicke darin, wie MR-Technologien die präzise Strahlentherapie voranbringen.
Hybrid
Universitätsspital Zürich, Rämistrasse 100, 8091 Zürich
Grosser Hörsaal PATH / D22
13.11.2026
08:45 - 16:00
5 SRO Credits
Kostenlos
| 08:45 | Registration, Coffee and Gipfeli |
| 09:15 | Welcome & Introduction Sebastian M. Christ, University Hospital Zurich, Switzerland |
| Session 1: Clinical Impact of MR-in-RT Thomas Zilli, Ente Ospedaliero Cantonale, Switzerland and Daniel Aebersold, Inselspital, University Hospital Bern, Switzerland |
|
| 09:30 | MR-enhanced ART: What is the Clinical Evidence to date? Juliane Hörner-Rieber, University Hospital Düsseldorf, Germany |
| 09:50 | MR-enhanced ART in the Thorax: Managing Motion, Margins, and Risk Fabian Weykamp, University Hospital Heidelberg, Germany |
| 10:10 | MR-adaptive ART in the Head & Neck Space: Results of the MARTHA Study Panagiotis Balermpas, University Hospital Zurich, Switzerland |
| 10:30 | How to design the next generation of MR-enhanced ART clinical trials Michael Chuong, Wertheim Cancer Institute, Florida, USA |
| 10:50 | Coffee Break |
| Session 2: Implementing MR-in-RT Moderated by Jakob Liermann, Heidelberg University Hospital, Germany and Christoph Bert, University Hospital Erlangen / FAU Erlangen-Nürnberg, Germany |
|
| 11:20 | Implementing MR-in-RT at Scale: Lessons from Early Adopters Martin Fast, University Medical Center Utrecht, The Netherlands |
| 11:40 | Dose Accumulation in ART: Are We Measuring What We Think We Are? Francesca Albertini, Paul Scherrer Institut PSI, Aargau, Switzerland |
| 12:00 | Workflow, Throughput, Economics: Can MR-enhanced ART be sustainable? Tobias Finazzi, Kantonsspital Baden, Switzerland |
| 12:20 | Lunch Break |
| Session 3: Technology, AI & Advanced Imaging Moderated by Oliver Riesterer, Kantonsspital Aarau, Switzerland and Stephanie Corradini, LMU-Hospital Munich, Germany |
|
| 13:20 | Planning MR, MR-Only and MR-First Planning: Technology is ready – are we? Riccardo Dal Bello, Universitätsspital Zürich, Schweiz |
| 13:40 | Functional low-field MR, Radiomics, AI: What can we translate into clinics? Jessica Scholey, University of California San Francisco, California, USA |
| Session 4: Podium Discussion Moderated by Sebastian M. Christ, University Hospital Zurich, Switzerland |
|
| 14:00 | Podium Discussion: “Are we over-engineering RT through the use of MR?” Michael Chuong, Wertheim Cancer Institute, Florida, USA Stefanie Corradini, LMU-Hospital Munich, Germany Juliane Hörner-Rieber, University Hospital Düsseldorf, Germany Jessica Scholey, University of California San Francisco, California, USA |
| 14:45 | Closing Remarks Sebastian M. Christ, University Hospital Zurich, Switzerland |
| 15:00 | Coffee Break |
| Sitzung 5: Accela: Eine neue Generation der Linearbeschleunigertechnologie Moderation: Stephanie Tanadini-Lang, Universitätsspital Zürich, Schweiz |
|
| 16:30 | Closing Apéro |
Magnetic Resonance (MR) in radiation therapy is redefining precision oncology by enabling superior soft-tissue imaging, adaptive treatment, and real-time monitoring. Its clinical impact is increasingly evident across tumor sites, while technological advances—from functional low-field MR to AI-driven planning—are unlocking new opportunities for personalized care.
Its clinical impact is increasingly evident across tumor sites, while technological advances—from functional low-field MR to AI-driven planning—are unlocking new opportunities for personalized care. Participants will gain practical perspectives from early adopters, learn about evolving adaptive treatment strategies, and discuss future directions in workflow optimization, sustainability, and clinical research.
Participants will gain practical perspectives from early adopters, learn about evolving adaptive treatment strategies, and discuss future directions in workflow optimization, sustainability, and clinical research.
Freundliche Grüsse
Matthias Guckenberger & Sebastian M. Christ
Please register by November 6, 2026.